Skip to Content

BioInvent International AB BOVNF

Morningstar Rating
$4.70 +1.72 (57.72%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

BOVNF is trading at a 212% premium.
Price
$4.68
Fair Value
$9.74
Uncertainty
Extreme
1-Star Price
$41.27
5-Star Price
$4.94
Economic Moat
Ypjj
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BOVNF is a good fit for your portfolio.

Trading Information

Previous Close Price
$2.98
Day Range
$4.704.70
52-Week Range
$2.984.70
Bid/Ask
$2.63 / $3.63
Market Cap
$309.28 Mil
Volume/Avg
1,002 / 995

Key Statistics

Price/Earnings (Normalized)
Price/Sales
8.53
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
109

Comparables

Valuation

Metric
BOVNF
MRSN
SNDX
Price/Earnings (Normalized)
Price/Book Value
1.929.313.46
Price/Sales
8.536.65
Price/Cash Flow
Price/Earnings
BOVNF
MRSN
SNDX

Financial Strength

Metric
BOVNF
MRSN
SNDX
Quick Ratio
13.343.438.87
Current Ratio
13.453.518.93
Interest Coverage
−34.91−1,182.75
Quick Ratio
BOVNF
MRSN
SNDX

Profitability

Metric
BOVNF
MRSN
SNDX
Return on Assets (Normalized)
−22.22%−41.22%−42.31%
Return on Equity (Normalized)
−23.74%−196.75%−46.19%
Return on Invested Capital (Normalized)
−23.36%−129.55%−51.17%
Return on Assets
BOVNF
MRSN
SNDX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
BkxkmmvppRfrq$631.5 Bil
Vertex Pharmaceuticals Inc
VRTX
WjdzdvtfMdhrbts$121.0 Bil
Regeneron Pharmaceuticals Inc
REGN
QrhpxmpNrgdfqj$116.0 Bil
Moderna Inc
MRNA
NjnvlwhpFcvf$51.1 Bil
argenx SE ADR
ARGX
QdhlzbxsNqpn$23.7 Bil
Alnylam Pharmaceuticals Inc
ALNY
QhvyvqmpCbpjrx$21.0 Bil
BioNTech SE ADR
BNTX
YflqcmttjCpzm$20.4 Bil
Biomarin Pharmaceutical Inc
BMRN
RnydllxtYldwlpm$15.9 Bil
United Therapeutics Corp
UTHR
PbvbllyxHss$14.0 Bil
Incyte Corp
INCY
BkhvhkfBbklsw$12.5 Bil

Sponsor Center